Short answer
Lantheus Holdings, Inc. (LNTH) filed its fiscal 2025 10-K annual report with the SEC on Feb 26, 2026. It reported revenue of $1.5B (+0.5% year over year) and net income of $234M.
- Top risk flagged: No specific or timely regulatory or legal risk detailed in the text
FY2025 key financial metrics · XBRL
- Revenue
- $1.5B
- +0.5% YoY
- Net income
- $234M
- −25.2% YoY
- Operating margin
- 20.2%
- −9.6 pp YoY
- Gross margin
- 61.1%
- −3.3 pp YoY
- EPS (diluted)
- $3.41
- −21.8% YoY
- ROE
- 21.4%
- −7.3 pp YoY
- Operating cash flow
- $390M
- −28.4% YoY
Source: XBRL data from the Lantheus Holdings, Inc. (LNTH) FY2025 10-K on SEC EDGAR. USD.
Lantheus Holdings, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Development, manufacturing, and commercialization of radiopharmaceutical and diagnostic imaging products
- New launches: Acquisitions of Life Molecular (Neuraceq) and Evergreen, adding diagnostic imaging and CDMO services to portfolio in 2025
- Strategic shifts: Discontinued AZEDRA in Q1 2024, sold TechneLite in 2026, focusing on higher-growth assets like Neuraceq and CDMO services
- Notable metric: General & administrative expenses up $81.4M (42%) in 2025 due to acquisitions and litigation costs
- Distinct fact: Paid $250M upfront for PNT2002 license but ceased development, deciding not to pursue NDA or further investment
Management Discussion & Analysis
- Operating cash flow $390.1M in 2025 vs $544.8M in 2024, decrease driven by acquisitions and working capital timing
- Investing cash outflow $627.1M in 2025 vs $204.5M in 2024, 2025 includes $268.9M for Evergreen and $306.7M for Life Molecular acquisitions
- Financing cash used $316.5M in 2025 vs $115.7M in 2024, due to $300M stock repurchase in 2025 vs $100M in 2024
- Management highlights increased credit facility to $750M with extended maturity to 2029, expects cash plus credit availability to cover needs next 12+ months
Risk Factors
- No specific or timely regulatory or legal risk detailed in the text
- No concrete geopolitical or macroeconomic threat exposure disclosed
- Operational risk from cybersecurity and data privacy requiring quarterly monitoring and oversight by Audit Committee
- No named competitor or technology disrupting market environment mentioned
- Key-person risk with CIO and CISO critical for risk management, each having ~30 years of industry experience
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.